Jamieson is pleased to announce that it has advised the management team of SOFIE Biosciences on the substantial growth investment into the business by Trilantic North America.
Headquartered in Dulles, Virginia and with 15 locations across the United States, SOFIE is a leading player in the radiopharmaceutical sector, manufacturing more than 567,000 doses annually on behalf of its partners and customers. The growth investment from Trilantic North America will capitalize the business to execute on several growth initiatives, including expanding capacity and points of presence to improve patient access to its growing portfolio of radiopharmaceutical products.
Mike Sirkin, Mark Wasserberger, and Fionn Dillon Kelly advised Patrick Phelps (Co-Founder and CEO) and his management team on their reinvestment into the new structure and the terms of the new MIP.
Jamieson Corporate Finance US, LLC is a member of FINRA/SIPC
